Compare Invesco Ltd. (IVZ) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Ltd. vs Tilray Brands Inc — how do they compare? Invesco Ltd. trades at $29.51 (market cap $13.28B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Invesco Ltd. is far larger — about 25× Tilray Brands Inc's market cap, and Invesco Ltd. pays a 2.86% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco Ltd. for 77 Days and Tilray Brands Inc for 31 Days on average.
| IVZ | TLRY | |
|---|---|---|
Market Cap | $13.28B | $530.54M |
Volume | 3,698,033 | 9,099,075 |
Sector | Financials | Health |
52-Week High | $33.31 | $17.20 |
52-Week Low | $22.44 | $3.54 |
Typical Hold Time | 77 Days | 31 Days |
Enterprise Value | $23.45B | $684.46M |
Dividend Yield | 2.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IVZ trades at $30.09, down 1.34% on the day, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $281.70 million in 2025 despite revenue growth to $6.38 billion, though recent earnings beats in Q4 2025 and Q2 2026 show some operational resilience. Analyst consensus is mixed with a $33.14 price target, and the firm continues expanding its ETF suite, including the recent launch of the Invesco Nasdaq International Innovators 100 ETF.
The outlook remains cautious due to negative profitability margins and bearish technicals, but the absence of sell ratings and a dividend payment provide some support. Key risks include sustained negative net income and competitive pressures in the asset management sector, while potential upside hinges on improved earnings and AUM growth momentum.
TLRY trades at $3.59, down 3.36% on the day and near 52-week lows, with a bearish technical signal. The company reported revenue of $821.31M for 2025 but posted a net loss of -$2.19B, missing earnings expectations for four consecutive quarters. While analyst consensus shows 70% hold ratings, the stock faces significant profitability challenges with negative margins and cash flow concerns despite some revenue growth projections.
The outlook remains challenging with persistent losses and negative cash flow, though the stock trades at discounted valuation multiples. Key risks include ongoing profitability struggles and cannabis regulatory uncertainty. Potential catalysts include upcoming Q1 2027 earnings on October 8, 2026, and potential marijuana reform developments that could benefit the company's positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
